A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
Condition:   Influenza, Human Intervention:   Biological: H5N1 antigen combined with MF59 adjuvant Sponsor:   Seqirus Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2020 Category: Research Source Type: clinical trials